Project

A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma; Short Title: GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy iin patients with resexted melanoma

Automatically Closed · 2010 until 2015

Heinzerling Lucie